High Numbers of Differentiated Effector CD4 T Cells Are Found in Patients With Cancer and Correlate With Clinical Response After Neoadjuvant Therapy of Breast Cancer

Cancer Research - United States
doi 10.1158/0008-5472.can-13-2269
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Response to Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

Anti-Her2 CD4+ T-Helper Type 1 Response Is a Novel Immune Correlate to Pathologic Response Following Neoadjuvant Therapy in HER2-positive Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2015English

Decreased Numbers of CD4+ Naive and Effector Memory T Cells, and CD8+ Naïve T Cells, Are Associated With Trichloroethylene Exposure

Frontiers in Oncology
Cancer ResearchOncology
2012English

Neoadjuvant Therapy With Cisplatin in BRCA1-positive Breast Cancer Patients

Hereditary Cancer in Clinical Practice
OncologyGenetics
2011English

Relevance of Pathological Complete Response After Neoadjuvant Therapy for Breast Cancer

Breast Cancer: Basic and Clinical Research
Cancer ResearchOncology
2016English

Predictors of Recurrence in Breast Cancer Patients With a Pathologic Complete Response After Neoadjuvant Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2010English

Quality of Pathologic Response and Surgery Correlate With Survival for Patients With Completely Resected Bladder Cancer After Neoadjuvant Chemotherapy

Cancer
Cancer ResearchOncology
2009English

Pathologic Evaluation of Breast Cancer After Neoadjuvant Therapy

Journal of Pathology and Translational Medicine
Forensic MedicinePathologyHistology
2016English

Evaluation of Clinical and Pathological Response After Two Cycles of Neoadjuvant Chemotherapy on Sudanese Patients With Locally Advanced Breast Cancer

Ethiopian journal of health sciences
Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy